Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Oxford Science Enterprises (OSE), founded in 2015, is based in Oxford, England. The firm was established to support the commercialization of scientific research and innovation emerging from the University of Oxford. As the university's preferred investor, OSE is strategically positioned to leverage cutting-edge research and technology, facilitating the growth of early-stage science and technology companies.
Currently, OSE manages approximately $1.45 billion in assets under management (AUM) and has backed over 80 companies since its inception, maintaining a core active portfolio of around 40 companies. The firm operates primarily within the UK and Europe, focusing on pre-seed, seed, seed-plus, and Series A stages. OSE's unique relationship with the University of Oxford provides it with privileged access to deal flow from one of the world's leading research institutions.
Notable milestones include significant exits such as Oxford Ionics, which was acquired for $1.08 billion, and OrganOx, acquired for $1.5 billion, marking the largest acquisition of any UK university spinout. OSE's innovative approach to investment has garnered over £2.5 billion in commitments from more than 300 investors over the past decade.
Oxford Science Enterprises invests in early-stage companies across the life sciences, technology, and healthcare sectors. The firm primarily targets investments within the UK and Europe, focusing on pre-seed, seed, seed-plus, and Series A stages. OSE's investment strategy emphasizes the translation of scientific discoveries from the University of Oxford into market-ready solutions, ensuring a strong alignment with the university's research capabilities.
OSE typically invests between £50,000 and £25 million in its portfolio companies, reflecting a flexible approach to funding. The firm seeks founders who demonstrate a deep understanding of their scientific domain and possess the capability to translate complex research into viable commercial products. OSE also values strong teams with a proven track record in their respective fields, as well as innovative business models that address significant market needs.
In addition to financial support, OSE provides strategic guidance and access to top-tier research and talent from the University of Oxford, enhancing the growth potential of its portfolio companies. The firm is particularly interested in companies that can leverage deep tech and health tech innovations to create impactful solutions in the market.
Oxford Science Enterprises has a diverse portfolio that includes notable companies across various scientific fields. The firm has backed over 80 companies since its inception, with a core active portfolio of approximately 40. Key portfolio companies include:
These companies exemplify OSE's focus on translating scientific research into commercially viable products. The firm has achieved significant milestones with its portfolio, including high-value acquisitions and IPOs, reflecting its successful investment strategy.
Ed Bussey - CEO. Appointed in September 2023, Ed is a dynamic entrepreneur with a proven track record in founding and building successful tech-enabled companies.
Jack Edmondson - CIO. Also appointed in September 2023, Jack is an experienced investment professional with a deep understanding of the Oxford ecosystem.
Alexis Zervoglos - Senior Partner, Technology. Alexis brings extensive experience in technology investments and has been instrumental in identifying high-potential startups.
Katya Smirnyagina, PhD - Senior Partner, Life Sciences. Katya has a strong background in life sciences and plays a key role in evaluating biotech investments.
Dr. Ceri Morgan - Head of Late Stage Portfolio. Ceri oversees the late-stage investments and has a wealth of experience in scaling companies.
Sarah Shackelton - Chief Talent Officer. Sarah focuses on talent acquisition and development within the portfolio companies.
Craig Fox, PhD - Operating Partner, Life Sciences. Craig provides operational support and strategic insights to life sciences companies in the portfolio.
Startups interested in pitching to Oxford Science Enterprises should prepare a comprehensive pitch deck that includes details on the scientific foundation, market potential, and team expertise. OSE prefers warm introductions through their network but also accepts direct inquiries via their website.
Response times can vary, but founders should expect a thorough review process given the firm's focus on scientific rigor and market viability.
In March 2025, Oxford Science Enterprises secured a £100-175 million NAV financing facility from Deutsche Bank and Goldman Sachs, marking a significant achievement as one of the first early-stage VCs to complete such a facility.
June 2025 saw the acquisition of Oxford Ionics by IonQ for $1.08 billion, representing OSE's first unicorn exit. This company was spun out from a physics lab in 2019.
In August 2025, OrganOx was acquired by Terumo Corporation for $1.5 billion, the largest acquisition of any UK university spinout to date.
Additionally, in March 2025, OSE collaborated with Aviva Investors to make a £15 million investment, alongside a £6.6 million direct investment into portfolio company Alloyed.
What are Oxford Science Enterprises' investment criteria?
OSE invests in early-stage companies primarily in the life sciences, technology, and healthcare sectors. The firm focuses on pre-seed, seed, seed-plus, and Series A stages, seeking innovative solutions that translate scientific discoveries into market-ready products.
How can startups apply or pitch to OSE?
Startups interested in pitching to OSE should prepare a detailed business plan that outlines their scientific innovation, market potential, and team capabilities. Direct outreach through their website or networking within the University of Oxford ecosystem is encouraged.
What makes Oxford Science Enterprises different from other VCs?
OSE is uniquely positioned as the preferred investor of the University of Oxford, granting it privileged access to cutting-edge research and a strong pipeline of innovative startups. This relationship enhances OSE's ability to support the commercialization of scientific research.
What is the geographic scope of OSE's investments?
OSE primarily invests in companies located in the UK and Europe, focusing on regions with strong scientific research capabilities and innovation ecosystems.
What is the typical check size for investments?
OSE typically invests between £50,000 and £25 million in its portfolio companies, allowing for flexibility based on the specific needs of each startup.
What kind of post-investment involvement does OSE have?
OSE provides strategic support to its portfolio companies, leveraging its connections within the University of Oxford to offer access to research, talent, and resources. The firm also facilitates follow-on investments to optimize growth and exit opportunities.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.